Hyperbaric oxygen therapy is FDA-approved for one cancer-related indication: late radiation tissue injury. This page is about that approved use and the broader, growing evidence base for HBOT as supportive care for cancer survivors — addressing the long-term effects of cancer treatment that conventional medicine often cannot. It is not about treating cancer itself. That distinction matters scientifically, ethically, and legally, and it is the position the major HBOT research groups have consistently taken. With that framing established, the case for HBOT in cancer survivorship is unusually strong: a Cochrane meta-analysis, FDA approval, and emerging evidence in chemotherapy-induced cognitive impairment make this one of the most evidence-backed survivorship interventions available.
The Science: Repairing Treatment Damage, Not Treating Cancer
Cancer treatment — surgery, radiation, chemotherapy, and increasingly immunotherapy — saves lives. But it also damages healthy tissue, and that damage often persists long after the cancer is gone. Survivors live with the consequences for years or decades.
The damage falls into several categories:
### Late Radiation Tissue Injury
Radiation therapy damages blood vessels in treated tissue. Months to years later, this damage manifests as:
– Osteoradionecrosis — bone death, particularly in the jaw after head/neck radiation
– Radiation cystitis — chronic bladder inflammation and bleeding after pelvic radiation
– Radiation proctitis — chronic rectal inflammation after pelvic radiation
– Soft tissue radionecrosis — non-healing wounds in irradiated tissue
– Radiation fibrosis — progressive scarring and tissue stiffness
### Chemotherapy-Related Damage
Chemotherapy agents are systemic, affecting healthy tissue throughout the body:
– Chemotherapy-induced cognitive impairment (“chemo brain”) — persistent memory, attention, and processing-speed deficits
– Peripheral neuropathy — nerve damage causing tingling, numbness, or pain
– Cardiotoxicity — cardiac muscle damage from certain agents
– Mitochondrial damage — contributing to chronic fatigue
### Post-Surgical Healing
Surgical recovery in cancer patients is often complicated by prior radiation, chemotherapy, or compromised vascular supply.
HBOT addresses the common biological substrate behind all of these: damaged microcirculation, mitochondrial dysfunction, and chronic inflammation. The same regenerative cascade — angiogenesis, stem cell mobilization, reduced inflammation — that drives HBOT’s other applications applies here.
The Foundational Evidence: Cochrane Meta-Analysis
### Bennett et al., Cochrane Database (2016)
The most rigorous evidence in this space. A Cochrane systematic review and meta-analysis of 14 trials comprising 753 patients with late radiation tissue injury. Findings:
– Significant improvement in healing across multiple radiation injury types
– Particularly strong evidence for osteoradionecrosis of the jaw — HBOT is now standard of care
– Reduced morbidity from radiation cystitis and proctitis
– Foundation for FDA approval of HBOT in late radiation tissue injury
This is the strongest single piece of evidence for HBOT in cancer survivorship and the basis for its on-label, insurance-covered use in this population.
### Beyond Radiation Injury: Emerging Evidence
The evidence base is expanding into other survivorship issues:
– Chemotherapy-induced cognitive impairment (“chemo brain”): Preliminary trials show improvements in cognitive function in survivors with persistent cognitive symptoms
– Cancer-related fatigue: Mitochondrial recovery and reduced inflammation drive measurable improvements in fatigue scores in survivors
– Lymphedema: HBOT-driven angiogenesis supports lymphatic recovery
– Post-mastectomy reconstruction healing: Particularly after radiation, HBOT supports tissue viability for reconstruction
The evidence in these adjacent areas is earlier-stage than the radiation injury data, but the mechanism logic is consistent.
The Survivorship Protocol
### The Standard Protocol for Late Radiation Tissue Injury
The FDA-approved protocol is the strongest reference point:
– Pressure: 2.0–2.4 ATA in clinical settings (hard-shell hospital chambers)
– Oxygen concentration: 100%
– Session length: 90 minutes
– Cadence: 5 sessions per week
– Total sessions: 30–60 sessions, depending on severity and tissue type
This is typically delivered in hospital wound care centers and is generally insurance-covered for the on-label indication.
### The Home Protocol for Survivorship Maintenance
For broader survivorship use cases — chemo brain, chronic fatigue, post-treatment recovery — a home 1.5 ATA protocol is more practical:
– Pressure: 1.5 ATA
– Oxygen concentration: 95%
– Session length: 60 minutes
– Cadence: 5 sessions per week
– Total sessions: 40 sessions for the initial course; many survivors maintain at 1–2 sessions per week thereafter
### Critical: Coordination with Your Oncology Team
HBOT for survivorship should always be coordinated with your oncology team. There are specific considerations:
– Active cancer treatment: Most oncologists prefer HBOT after active treatment is complete, not during. There are exceptions for radiation injury occurring during ongoing treatment.
– Bleomycin chemotherapy: A specific chemo agent that is contraindicated with HBOT for at least several months after exposure. Always disclose chemotherapy history.
– Surveillance and follow-up: HBOT does not interfere with cancer surveillance imaging or biomarker testing.
The "Does HBOT Feed Cancer?" Question
An older concern in oncology held that elevated oxygen might promote cancer growth — the logic being that cancer cells need oxygen to proliferate. This concern has been substantially addressed by modern research, and current evidence does not support it.
Multiple studies have found:
– HBOT does not promote primary tumor growth in animal or human studies
– HBOT may sensitize hypoxic tumor regions to radiation therapy (the opposite of “feeding” cancer)
– No documented increased risk of cancer recurrence in HBOT-treated survivors
– Some preclinical evidence suggests HBOT may have anti-tumor effects in certain cancer types
The current consensus in the major hyperbaric medicine societies is that HBOT is safe in cancer survivors and may, in select circumstances, enhance cancer treatment outcomes. This is a meaningful shift from the older concerns and is reflected in current treatment guidelines.
That said: this site does not promote HBOT as a cancer treatment. The evidence base for HBOT in active cancer therapy is preliminary and the regulatory framework (FDA) does not support that claim. The scientifically grounded position — and the one we take here — is that HBOT is a survivorship and recovery tool, not a cancer therapy.
The Cochrane meta-analysis confirms HBOT improves healing of late radiation tissue injury — making it one of the most evidence-backed interventions available for cancer survivors.
— Bennett et al., Cochrane Database of Systematic Reviews (2016)